Vicore Pharma Holding AB (publ) announced that it has appointed Rohit Batta as Chief Medical Officer, effective November 26, 2018 and Göran Tornling as Senior Medical Advisor starting September 17, 2018. Dr. Batta will report to the CEO and join the company’s Executive Team. Both recruitments are important to bolster it's medical competencies in the pulmonary rare disease space. Dr. Rohit Batta has 18 years of experience as a medical doctor with an extensive background, leading medical and clinical development teams whilst developing drugs for rare diseases. His previous roles include Senior Director of Cell and Gene Therapy at GlaxoSmithKline (GSK) with responsibility for leading the clinical development team and defining the clinical strategy for haemoglobinopathy gene therapy medicines. He also led the global medical and late stage clinical development teams to launch the world's first gene therapy for patients with a pediatric rare disease. Dr. Göran Tornling has almost four decades' experience as a physician specializing in respiratory medicine. His previous roles include Executive Director Clinical Science and Strategy (Respiratory) at AstraZeneca R&D with responsibility for developing clinical strategies, including an IPF program which is Vicore's main indication. He was EVP and Head Research and Development at Orexo, responsible for research and preclinical development and pharmaceutical innovation and development.